Biotech Company Outlook to 2016 This analysis examines the outlook for companies in Datamonitor's Biotech peer set. The report encompasses insight into key strategic themes across the group of companies and identifies sales trends using 6-year prescription pharmaceutical sales forecasts for all the companies covered. Gain insight into Biotech companies strategic outlook across the next 6 years* Analyze sales forecasts by company, therapy area, lifecycle stage, and molecule type. Strategic insight into the prospects for Biotech companies over the next six years. Picking out key trends across the companies and comparing performance using a variety of cuts of forecast sales. Benchmark companies outlook against key rivals across Datamonitor's Biotech peer set* Analyze how peer set sales attributable to therapeutic proteins will come under increased threat from biosimilar competition through to 2016 Key findingsOverview of the Biotech peer setBiotech peer set prescription sales performance, 2004-16The Biotech company outlook to 2016INTRODUCTIONData sourcing[Missing title]Further readingSTRATEGIC INSIGHTBiotech peer set product growth drivers and resistors, 2010-16Monoclonal antibodies are the key long-term growth driversPipeline analysis: focus remains on core therapy areas with increasingly diverse molecule type strategiesTHE BIOTECH OUTLOOK TO 2016Key findingsOverview of Biotech to 2016Biotech prescription pharma sales performance, 2004-16Biotech landscape, 2010-16Biotech company analysisBiotech launch/core/expiry analysisBiotech therapy area analysisBiotech molecule type analysisAPPENDIXReferencesDatamonitor reportsExchange rates To order this report: Biotechnology Industry: Biotech Company Outlook to 2016